{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:44:46Z","timestamp":1793943886075,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1-AI110557"],"award-info":[{"award-number":["UM1-AI110557"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS080821"],"award-info":[{"award-number":["R01-NS080821"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["4T32HD007505-20"],"award-info":[{"award-number":["4T32HD007505-20"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Autoimmun Highlights"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s13317-017-0100-y","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T21:15:05Z","timestamp":1510780505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment"],"prefix":"10.1007","volume":"8","author":[{"given":"Fanny Huynh","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-3480","authenticated-orcid":false,"given":"Yang","family":"Mao-Draayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"issue":"2","key":"100_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","volume":"40","author":"JC Edwards","year":"2001","unstructured":"Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40(2):205\u2013211","journal-title":"Rheumatology"},{"issue":"6","key":"100_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMra0708875","volume":"359","author":"BD Cheson","year":"2008","unstructured":"Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma. N Engl J Med 359(6):613\u2013626. \n                    https:\/\/doi.org\/10.1056\/NEJMra0708875","journal-title":"N Engl J Med"},{"issue":"1","key":"100_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","volume":"180","author":"DJ DiLillo","year":"2008","unstructured":"DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM et al (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180(1):361\u2013371","journal-title":"J Immunol"},{"issue":"1","key":"100_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1124\/pr.109.002006","volume":"63","author":"P Engel","year":"2011","unstructured":"Engel P, Gomez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X (2011) Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 63(1):127\u2013156. \n                    https:\/\/doi.org\/10.1124\/pr.109.002006","journal-title":"Pharmacol Rev"},{"issue":"2","key":"100_CR5","first-page":"98","volume":"17","author":"D Paran","year":"2015","unstructured":"Paran D, Naparstek Y (2015) Is B cell-targeted therapy effective in systemic lupus erythematosus? Israel Med Assoc J 17(2):98\u2013103","journal-title":"Israel Med Assoc J"},{"issue":"8","key":"100_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","volume":"95","author":"HH Wang","year":"2015","unstructured":"Wang HH, Liu CW, Li YC, Huang YC (2015) Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol 95(8):928\u2013932. \n                    https:\/\/doi.org\/10.2340\/00015555-2116","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"100_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"issue":"1","key":"100_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","volume":"25","author":"T Robak","year":"2011","unstructured":"Robak T, Robak E (2011) New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25(1):13\u201325. \n                    https:\/\/doi.org\/10.2165\/11539590-000000000-00000","journal-title":"BioDrugs"},{"issue":"2","key":"100_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/art.33317","volume":"64","author":"W Rigby","year":"2012","unstructured":"Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA et al (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64(2):350\u2013359. \n                    https:\/\/doi.org\/10.1002\/art.33317","journal-title":"Arthritis Rheum"},{"issue":"8","key":"100_CR10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","volume":"71","author":"W Stohl","year":"2012","unstructured":"Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA et al (2012) Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 71(8):1289\u20131296. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2011-200706","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"100_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2217\/ijr.11.55","volume":"6","author":"JE Huffstutter","year":"2011","unstructured":"Huffstutter JE, Taylor J, Schectman J, Leszczynski P, Brzosko M, Sedarati F et al (2011) Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the phase III FEATURE trial. Int J Clin Rheumatol 6(6):689\u2013696. \n                    https:\/\/doi.org\/10.2217\/IJR.11.55","journal-title":"Int J Clin Rheumatol"},{"issue":"2","key":"100_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/art.33353","volume":"64","author":"PP Tak","year":"2012","unstructured":"Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y et al (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64(2):360\u2013370","journal-title":"Arthritis Rheum"},{"issue":"9","key":"100_CR13","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/art.23732","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J et al (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58(9):2652\u20132661. \n                    https:\/\/doi.org\/10.1002\/art.23732","journal-title":"Arthritis Rheum"},{"issue":"2","key":"100_CR14","doi-asserted-by":"publisher","first-page":"e87379","DOI":"10.1371\/journal.pone.0087379","volume":"9","author":"P Emery","year":"2014","unstructured":"Emery P, Rigby W, Tak PP, Dorner T, Olech E, Martin C et al (2014) Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS ONE 9(2):e87379. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0087379","journal-title":"PLoS ONE"},{"issue":"3","key":"100_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3899\/jrheum.110994","volume":"39","author":"M Harigai","year":"2012","unstructured":"Harigai M, Tanaka Y, Maisawa S, Tanimura K, Takahashi H, Urata Y et al (2012) Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. J Rheumatol 39(3):486\u2013495. \n                    https:\/\/doi.org\/10.3899\/jrheum.110994","journal-title":"J Rheumatol"},{"issue":"12","key":"100_CR16","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1136\/ard.2011.151522","volume":"70","author":"PC Taylor","year":"2011","unstructured":"Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70(12):2119\u20132125. \n                    https:\/\/doi.org\/10.1136\/ard.2011.151522","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"100_CR17","doi-asserted-by":"publisher","first-page":"e0157961","DOI":"10.1371\/journal.pone.0157961","volume":"11","author":"E Quattrocchi","year":"2016","unstructured":"Quattrocchi E, Ostergaard M, Taylor PC, van Vollenhoven RF, Chu M, Mallett S et al (2016) Safety of repeated open-label treatment courses of intravenous ofatumumab, a human ANTI-CD20 monoclonal antibody, in rheumatoid arthritis: results from three clinical trials. PLoS ONE 11(6):e0157961. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0157961","journal-title":"PLoS ONE"},{"issue":"8","key":"100_CR18","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1002\/art.27524","volume":"62","author":"M \u00d8stergaard","year":"2010","unstructured":"\u00d8stergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT et al (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I\/II study. Arthritis Rheum 62(8):2227\u20132238. \n                    https:\/\/doi.org\/10.1002\/art.27524","journal-title":"Arthritis Rheum"},{"issue":"7","key":"100_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3899\/jrheum.121118","volume":"40","author":"R Kurrasch","year":"2013","unstructured":"Kurrasch R, Brown JC, Chu M, Craigen J, Overend P, Patel B et al (2013) Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol 40(7):1089\u20131096. \n                    https:\/\/doi.org\/10.3899\/jrheum.121118","journal-title":"J Rheumatol"},{"key":"100_CR20","doi-asserted-by":"publisher","first-page":"CD009130","DOI":"10.1002\/14651858.CD009130.pub3","volume":"12","author":"D He","year":"2013","unstructured":"He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H (2013) Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 12:CD009130. \n                    https:\/\/doi.org\/10.1002\/14651858.CD009130.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"100_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460\u2013471. \n                    https:\/\/doi.org\/10.1002\/ana.21867","journal-title":"Ann Neurol"},{"issue":"3","key":"100_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"3","key":"100_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"issue":"9805","key":"100_CR24","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, O\u2019Connor P, Bar-Or A, Barkhof F et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805):1779\u20131787. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)61649-8","journal-title":"Lancet"},{"issue":"7","key":"100_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","volume":"82","author":"PS Sorensen","year":"2014","unstructured":"Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E et al (2014) Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 82(7):573\u2013581. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000000125","journal-title":"Neurology"},{"issue":"10 Supplement","key":"100_CR26","first-page":"17","volume":"82","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Grove R, Austin D, Tolson J, Vanmeter S, Lewis E et al (2014) The MIRROR Study: a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and MRI efficacy of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis (RRMS) (S23.006). Neurology 82(10 Supplement):17\u201321","journal-title":"Neurology"},{"key":"100_CR27","unstructured":"Efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing multiple sclerosis [database on the Internet]. National library of medicine (US). 2000. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02792218?term=Ofatumumab+multiple+sclerosis&rank=1\n                    \n                   NLM Identifier: NCT02792218. Accessed 10 Jan 2017"},{"issue":"9","key":"100_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1177\/0961203309106174","volume":"18","author":"M Ramos-Casals","year":"2009","unstructured":"Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18(9):767\u2013776. \n                    https:\/\/doi.org\/10.1177\/0961203309106174","journal-title":"Lupus"},{"issue":"1","key":"100_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233. \n                    https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"issue":"4","key":"100_CR30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64(4):1215\u20131226. \n                    https:\/\/doi.org\/10.1002\/art.34359","journal-title":"Arthritis Rheum"},{"issue":"6","key":"100_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD et al (2012) American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64(6):797\u2013808. \n                    https:\/\/doi.org\/10.1002\/acr.21664","journal-title":"Arthritis Care Res"},{"issue":"9","key":"100_CR32","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA et al (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368\u20132379. \n                    https:\/\/doi.org\/10.1002\/art.38037","journal-title":"Arthritis Rheum"},{"issue":"8","key":"100_CR33","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG et al (2002) Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46(8):2121\u20132131. \n                    https:\/\/doi.org\/10.1002\/art.10461","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"100_CR34","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar3910","volume":"15","author":"V Reddy","year":"2013","unstructured":"Reddy V, Jayne D, Close D, Isenberg D (2013) B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Therapy 15(Suppl 1):S2. \n                    https:\/\/doi.org\/10.1186\/ar3910","journal-title":"Arthritis Res Therapy"},{"issue":"4","key":"100_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","volume":"44","author":"H Tahir","year":"2005","unstructured":"Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA (2005) Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology 44(4):561\u2013562. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keh533","journal-title":"Rheumatology"},{"issue":"2","key":"100_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","volume":"166","author":"B Horvath","year":"2012","unstructured":"Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF (2012) Low-dose rituximab is effective in pemphigus. Br J Dermatol 166(2):405\u2013412. \n                    https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10663.x","journal-title":"Br J Dermatol"},{"issue":"6","key":"100_CR37","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/archdermatol.2011.3320","volume":"148","author":"S Matsukura","year":"2012","unstructured":"Matsukura S, Knowles SR, Walsh S, Shear NH (2012) Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol 148(6):734\u2013739. \n                    https:\/\/doi.org\/10.1001\/archdermatol.2011.3320","journal-title":"Arch Dermatol"},{"issue":"3","key":"100_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","volume":"68","author":"YA Leshem","year":"2013","unstructured":"Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D (2013) Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 68(3):404\u2013411. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2012.08.010","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"100_CR39","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","volume":"148","author":"L Lunardon","year":"2012","unstructured":"Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP et al (2012) Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 148(9):1031\u20131036. \n                    https:\/\/doi.org\/10.1001\/archdermatol.2012.1522","journal-title":"Arch Dermatol"},{"issue":"12","key":"100_CR40","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","volume":"150","author":"CT Ellebrecht","year":"2014","unstructured":"Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM et al (2014) Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol 150(12):1331\u20131335. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2014.1939","journal-title":"JAMA Dermatol"},{"issue":"3","key":"100_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"RF van Vollenhoven","year":"2010","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558\u2013567. \n                    https:\/\/doi.org\/10.3899\/jrheum.090856","journal-title":"J Rheumatol"},{"issue":"5","key":"100_CR42","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262(5):1115\u20131119. \n                    https:\/\/doi.org\/10.1007\/s00415-014-7532-3","journal-title":"J Neurol"},{"issue":"5","key":"100_CR43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bjh.12448","volume":"162","author":"HA Liebman","year":"2013","unstructured":"Liebman HA, Saleh MN, Bussel JB, Negrea OG, Horne H, Wegener WA et al (2013) Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol 162(5):693\u2013701. \n                    https:\/\/doi.org\/10.1111\/bjh.12448","journal-title":"Br J Haematol"},{"issue":"7","key":"100_CR44","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94(7):2217\u20132224","journal-title":"Blood"},{"issue":"8","key":"100_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7748\/cnp.14.8.29.s22","volume":"14","author":"S Liptrott","year":"2015","unstructured":"Liptrott S, Crosbie N, Sugino MS, Bratke R, Mendoza M, Sayyed P (2015) Practical experience with rituximab subcutaneous. Cancer Nursing Pract 14(8):29\u201337. \n                    https:\/\/doi.org\/10.7748\/cnp.14.8.29.s22","journal-title":"Cancer Nursing Pract"},{"issue":"5","key":"100_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bcp.12662","volume":"80","author":"S Assouline","year":"2015","unstructured":"Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M et al (2015) Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol 80(5):1001\u20131009. \n                    https:\/\/doi.org\/10.1111\/bcp.12662","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"100_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0961203315622819","volume":"25","author":"CE Henegar","year":"2016","unstructured":"Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, Haight B (2016) Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus 25(6):617\u2013626. \n                    https:\/\/doi.org\/10.1177\/0961203315622819","journal-title":"Lupus"},{"issue":"11","key":"100_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11908-016-0543-8","volume":"18","author":"D Saylor","year":"2016","unstructured":"Saylor D, Venkatesan A (2016) Progressive multifocal leukoencephalopathy in HIV-uninfected individuals. Curr Infect Dis Rep 18(11):33. \n                    https:\/\/doi.org\/10.1007\/s11908-016-0543-8","journal-title":"Curr Infect Dis Rep"},{"key":"100_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-070912-133235","volume":"65","author":"M Faurschou","year":"2014","unstructured":"Faurschou M, Jayne DR (2014) Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med 65:263\u2013278. \n                    https:\/\/doi.org\/10.1146\/annurev-med-070912-133235","journal-title":"Annu Rev Med"},{"issue":"2","key":"100_CR50","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","volume":"6","author":"KM Kanth","year":"2016","unstructured":"Kanth KM, Solorzano GE, Goldman MD (2016) PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 6(2):e17\u2013e19. \n                    https:\/\/doi.org\/10.1212\/CPJ.0000000000000202","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"100_CR51","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13365-014-0303-1","volume":"21","author":"S Chahin","year":"2015","unstructured":"Chahin S, Berger JR (2015) A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J Neurovirol 21(6):623\u2013631. \n                    https:\/\/doi.org\/10.1007\/s13365-014-0303-1","journal-title":"J Neurovirol"},{"issue":"12","key":"100_CR52","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy ES, Calabrese LH (2009) Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60(12):3761\u20133765. \n                    https:\/\/doi.org\/10.1002\/art.24966","journal-title":"Arthritis Rheum"},{"issue":"20","key":"100_CR53","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20):4834\u20134840. \n                    https:\/\/doi.org\/10.1182\/blood-2008-10-186999","journal-title":"Blood"},{"issue":"20","key":"100_CR54","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K et al (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074\u20132081. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000003331","journal-title":"Neurology"},{"issue":"10 Supplement","key":"100_CR55","first-page":"P4","volume":"82","author":"J Avila","year":"2014","unstructured":"Avila J, Han J, Zaydan I (2014) Progressive multifocal leukoencephalopathy associated with ofatumumab presenting as alexia without agraphia: a case report. Neurology 82(10 Supplement):P4\u2013P319","journal-title":"Neurology"},{"issue":"4","key":"100_CR56","first-page":"370","volume":"6","author":"SS Evans","year":"2015","unstructured":"Evans SS, Clemmons AB (2015) Obinutuzumab: a novel anti-CD20 monoclonal antibody for chronic lymphocytic leukemia. J Adv Pract Oncol 6(4):370\u2013374","journal-title":"J Adv Pract Oncol"},{"issue":"21","key":"100_CR57","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1182\/blood.V124.21.3319.3319","volume":"124","author":"S Ringelstein-Harlev","year":"2014","unstructured":"Ringelstein-Harlev S, Avivi I, Shivtiel-Arad S, Katz T (2014) Chronic lymphocytic leukemia cells acquire a regulatory B-cell phenotype modified by PD1 signaling. Blood 124(21):3319","journal-title":"Blood"},{"issue":"10","key":"100_CR58","first-page":"26","volume":"41","author":"K Panesar","year":"2016","unstructured":"Panesar K (2016) Biosimilars: current approvals and pipeline agents. US Pharmacist 41(10):26\u201329","journal-title":"US Pharmacist"},{"key":"100_CR59","unstructured":"Gever J (2015) Rituximab: don\u2019t count It out as MS treatment. MedPage Today. Retrieved from \n                    http:\/\/www.medpagetoday.com\/meetingcoverage\/ectrims\/54060"},{"key":"100_CR60","unstructured":"Tobias E (2017) MS drug treatment costs start the year headed up. Multiple Sclerosis News Today. Retrieved from \n                    https:\/\/multiplesclerosisnewstoday.com\/2017\/01\/13\/ms-drug-treatment-costs-start-year-headed-up\/"},{"issue":"21","key":"100_CR61","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","volume":"84","author":"DM Hartung","year":"2015","unstructured":"Hartung DM, Bourdette DN, Ahmed SM, Whitham RH (2015) The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology 84(21):2185\u20132192. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000001608","journal-title":"Neurology"},{"key":"100_CR62","unstructured":"Thomas K (2017) F.D.A. Approves first drug to treat severe multiple sclerosis. The New York times. Retrieved from \n                    https:\/\/www.nytimes.com\/2017\/03\/28\/health\/fda-drug-approved-multiplesclerosis-ocrevus.html?_r=0"},{"issue":"6","key":"100_CR63","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","volume":"186","author":"L Bologna","year":"2011","unstructured":"Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M et al (2011) Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 186(6):3762\u20133769. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1000303","journal-title":"J Immunol"}],"container-title":["Autoimmunity Highlights"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13317-017-0100-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13317-017-0100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13317-017-0100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T06:31:50Z","timestamp":1589437910000},"score":1,"resource":{"primary":{"URL":"https:\/\/autoimmunhighlights.biomedcentral.com\/articles\/10.1007\/s13317-017-0100-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1007\/s13317-017-0100-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732130936.793564282","asserted-by":"object"}]},"ISSN":["2038-0305","2038-3274"],"issn-type":[{"value":"2038-0305","type":"print"},{"value":"2038-3274","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]},"assertion":[{"value":"17 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FHD and EAM have nothing to disclose. YMD has served as a consultant and\/or received grant support from: Acorda, Bayer Pharmaceutical, Biogen Idec, EMD Serono, Genzyme, Novartis, Questor, Genentech, and Teva Neuroscience.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This is a review article about clinical trials in which the participants had informed consent. No identifying information was used in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"12"}}